Effects of DNA topoisomerase IIα splice variants on acquired drug resistance

Abstract

DNA topoisomerase IIα (170 kDa, TOP2α/170) induces transient DNA double-strand breaks in proliferating cells to resolve DNA topological entanglements during chromosome condensation, replication, and segregation. Therefore, TOP2α/170 is a prominent target for anticancer drugs whose clinical efficacy is often compromised due to chemoresistance. Although many resistance mechanisms have been defined, acquired resistance of human cancer cell lines to TOP2α interfacial inhibitors/poisons is frequently associated with a reduction of Top2α/170 expression levels. Recent studies by our laboratory, in conjunction with earlier findings by other investigators, support the hypothesis that a major mechanism of acquired resistance to TOP2α-targeted drugs is due to alternative RNA processing/splicing. Specifically, several TOP2α mRNA splice variants have been reported which retain introns and are translated into truncated TOP2α isoforms lacking nuclear localization sequences and subsequent dysregulated nuclear-cytoplasmic disposition. In addition, intron retention can lead to truncated isoforms that lack both nuclear localization sequences and the active site tyrosine (Tyr805) necessary for forming enzyme-DNA covalent complexes and inducing DNA damage in the presence of TOP2α-targeted drugs. Ultimately, these truncated TOP2α isoforms result in decreased drug activity against TOP2α in the nucleus and manifest drug resistance. Therefore, the complete characterization of the mechanism(s) regulating the alternative RNA processing of TOP2α pre-mRNA may result in new strategies to circumvent acquired drug resistance. Additionally, novel TOP2α splice variants and truncated TOP2α isoforms may be useful as biomarkers for drug resistance, prognosis, and/or direct future TOP2α-targeted therapies.

Keywords

DNA topoisomerase IIα / chemoresistance / alternative splicing / intron retention / topoisomerase IIα interfacial inhibitors/poisons

References

[1] Deweese JE.The DNA cleavage reaction of topoisomerase II: wolf in sheep’s clothing..Nucleic Acids Res2009;37:738-48 PMCID:PMC2647315

[2] Vos SM,Schmidt BH.All tangled up: how cells direct, manage and exploit topoisomerase function..Nat Rev Mol Cell Biol2011;12:827-41 PMCID:PMC4351964

[3] Chen SH,Hsieh TS.New mechanistic and functional insights into DNA topoisomerases..Annu Rev Biochem2013;82:139-70

[4] Pommier Y,Huang SN.Roles of eukaryotic topoisomerases in transcription, replication and genomic stability..Nat Rev Mol Cell Biol2016;17:703-21

[5] Nitiss JL.Targeting DNA topoisomerase II in cancer chemotherapy..Nat Rev Cancer2009;9:338-50 PMCID:PMC2748742

[6] Pommier Y.Interfacial inhibitors: targeting macromolecular complexes..Nat Rev Drug Discov2011;11:25-36

[7] Pommier Y.Drugging topoisomerases: lessons and challenges..ACS Chem Biol2013;8:82-95 PMCID:PMC3549721

[8] Delgado JL,Chan NL.Topoisomerases as anticancer targets..Biochem J2018;475:373-98 PMCID:PMC6110615

[9] Economides MP,Borthakur G.Topoisomerase II inhibitors in AML: past, present, and future..Expert Opin Pharmacother2019;20:1637-44

[10] Edwardson DW,Chewchuk S,Mapletoft JPJ.Role of drug metabolism in the cytotoxicity and clinical efficacy of anthracyclines..Curr Drug Metab2015;16:412-26 PMCID:PMC5398089

[11] Shanbhag S.Hodgkin lymphoma: a review and update on recent progress..CA Cancer J Clin2018;68:116-32 PMCID:PMC5842098

[12] National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Small Cell Lung Cancer (Version 1.2020). Available from: https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf [Last accessed on 19 Feb 2020]

[13] Zhao H,Liu H.Comparison and discussion of the treatment guidelines for small cell lung cancer..Thorac Cancer2018;9:769-74 PMCID:PMC6026606

[14] Greene J.The role of anthracyclines in the treatment of early breast cancer..J Oncol Pharm Pract2015;21:201-12

[15] Blum JL,Yothers G,Geyer CE Jr.Anthracyclines in early breast cancer: the ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology)..J Clin Oncol2017;35:2647-55 PMCID:PMC5549453

[16] Owattanapanich W,Kungwankiattichai S,Kuchutrakool T.Efficacy and toxicity of idarubicin versus high-dose daunorubicin for induction chemotherapy in adult acute myeloid leukemia: a systematic review and meta-analysis..Clin Lymphoma Myeloma Leuk2018;18:814-21.e3

[17] National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia (Version 2.2020). Available from: https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf [Last accessed on 19 Feb 2020]

[18] Burgess DJ,Zender L,Ma B.Topoisomerase levels determine chemotherapy response in vitro and in vivo..Proc Natl Acad Sci U S A2008;105:9053-58 PMCID:PMC2435590

[19] Pilati P,Mocellin S.Cancer resistance to type II topoisomerase inhibitors..Curr Med Chem2012;19:3900-06

[20] Ganapathi RN.Mechanisms regulating resistance to inhibitors of topoisomerase II..Front Pharmacol2013;4:89 PMCID:PMC3729981

[21] Capelôa T,Zampieri LX,Sonveaux P.Metabolic and non-metabolic pathways that control cancer resistance to anthracyclines..Semin Cell Dev Biol2020;98:181-91

[22] Zahreddine H.Mechanisms and insights into drug resistance in cancer..Front Pharmacol2013;4:28 PMCID:PMC3596793

[23] Cree IA.Molecular chess? Hallmarks of anti-cancer drug resistance..BMC Cancer2017;17:10 PMCID:PMC5214767

[24] Lee Y.Mechanisms and regulation of alternative pre-mRNA splicing..Annu Rev Biochem2015;84:291-323 PMCID:PMC4526142

[25] Boutz PL,Sharp PA.Detained introns are a novel, widespread class of post-transcriptionally spliced introns..Genes Dev2015;29:63-80 PMCID:PMC4281565

[26] Wong JJ,Ritchie W.Intron retention in mRNA: no longer nonsense: known and putative roles of intron retention in normal and disease biology..Bioessays2015;38:41-9

[27] Kurosaki T.Nonsense-mediated mRNA decay in humans at a glance..J Cell Sci2016;129:461-7 PMCID:PMC4760306

[28] Li Y,Fitzgerald MP,Rekosh D.An NXF1 mRNA with a retained intron is expressed in hippocampal and neocortical neurons and is translated into a protein that functions as an Nxf1 cofactor..Mol Biol Cell2016;27:3903-12 PMCID:PMC5170612

[29] Uzor S,Bowler E,Wilson I.Autoregulation of the human splice factor kinase CLK1 through exon skipping and intron retention..Gene2018;670:46-54

[30] Shoubridge C,Grinton B,Scheffer IE.Splice variant in ARX leading to loss of C-terminal region in a boy with intellectual disability and infantile onset developmental and epileptic encephalopathy..Am J Med Genet A2019;179:1483-90

[31] Wang C.A novel RNA variant of human concentrative nucleoside transporter 1 (hCNT1) that is a potential cancer biomarker..Exp Hematol Oncol2019;8:18 PMCID:PMC6704654

[32] Harker WG,Parr RL.Selective use of an alternative stop codon and polyadenylation signal within intron sequences leads to a truncated topoisomerase II alpha messenger RNA and protein in human HL-60 leukemia cells selected for resistance to mitoxantrone..Cancer Res1995;55:4962-71

[33] Yu Q,Sparks KE.Two COOH-terminal truncated cytoplasmic forms of topoisomerase II alpha in a VP-16-selected lung cancer cell line result from partial gene deletion and alternative splicing..Biochemistry1997;36:5868-77

[34] Mo YY.Heterogeneous expression of DNA topoisomerase II alpha isoforms in tumor cell lines..Oncol Res1997;9:193-204

[35] Kanagasabai R,Karmahapatra S,Ellis J.Alternative RNA processing of topoisomerase iialpha in etoposide-resistant human leukemia K562 cells: intron retention results in a novel c-terminal truncated 90-kDa isoform..J Pharmacol Exp Ther2017;360:152-63

[36] Kanagasabai R,Kientz CA,Hernandez VA.The novel C-terminal truncated 90-kDa isoform of topoisomerase IIalpha (TOP2alpha/90) is a determinant of etoposide resistance in K562 leukemia cells via heterodimerization with the TOP2alpha/170 isoform..Mol Pharmacol2018;93:515-25

[37] Lang AJ,Cummings HJ,Gerlach JH.Structural organization of the human TOP2A and TOP2B genes..Gene1998;221:255-66

[38] Tsai-Pflugfelder M,Liu AA,Whang-Peng J.Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22..Proc Natl Acad Sci U S A1988;85:7177-81 PMCID:PMC282147

[39] Dong KC.Structural basis for gate-DNA recognition and bending by type IIA topoisomerases..Nature2007;450:1201-5

[40] Wendorff TJ,Heslop P,Berger JM.The structure of DNA-bound human topoisomerase II a: conformational mechanisms for coordinating inter-subunit interactions with DNA cleavage..J Mol Biol2012;424:109-24 PMCID:PMC3584591

[41] Frère V,Monnot M,Fermandjian S.A peptide fragment of human DNA topoisomerase II alpha forms a stable coiled-coil structure in solution..J Biol Chem1995;270:17502-07

[42] Berger JM,Harrison SC.Structure and mechanism of DNA topoisomerase II..Nature1996;379:225-22

[43] Frère-Gallois V,Scala D,Fermandjian S.Peptide fragments of DNA topoisomerase II with helix-forming and coiled-coil-forming properties act as inhibitors of the enzyme..Eur J Biochem1997;249:142-8

[44] Kroll DJ.Homologous and heterologous protein-protein interactions of human DNA topoisomerase II alpha..Arch Biochem Biophys1997;345:175-84

[45] Bjergbaek L,Westergaard O.Using a biochemical approach to identify the primary dimerization regions in human DNA topoisomerase II alpha..J Biol Chem1999;274:26529-36

[46] Mirski SE,Cummings HJ,Greer PA.Bipartite nuclear localization signals in the C terminus of human topoisomerase II alpha..Exp Cell Res1997;237:452-5

[47] Mirski SE,Cole SP.Sequence determinants of nuclear localization in the alpha and beta isoforms of human topoisomerase II..Exp Cell Res1999;251:329-39

[48] Kim D,Salzberg SL.HISAT: a fast spliced aligner with low memory requirements..Nat Methods2015;12:357-60 PMCID:PMC4655817

[49] Robinson JT,Winckler W,Lander ES.Integrative genomics viewer..Nat Biotechnol2011;29:24-6 PMCID:PMC3346182

[50] Harker WG,Dalton WS,Trent JM.Multidrug resistance in mitoxantrone-selected HL-60 leukemia cells in the absence of P-glycoprotein overexpression..Cancer Res1989;49:4542-9

[51] Harker WG,Drake FH.Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase II beta isoform..Biochemistry1991;30:9953-61

[52] Lane AB,Clarke DJ.A novel chromatin tether domain controls topoisomerase IIα dynamics and mitotic chromosome formation..J Cell Biol2013;203:471-86 PMCID:PMC3824022

[53] Feldhoff PW,Cole SP.Altered subcellular distribution of topoisomerase II alpha in a drug-resistant human small cell lung cancer cell line..Cancer Res1994;54:756-62

[54] Mirski SE.Cytoplasmic localization of a mutant M(r) 160,000 topoisomerase II alpha is associated with the loss of putative bipartite nuclear localization signals in a drug-resistant human lung cancer cell line..Cancer Res1995;55:2129-34

[55] Ritke MK.Altered gene expression in human leukemia K562 cells selected for resistance to etoposide..Biochem Pharmacol1993;46:2007-20

[56] Ritke MK,Allan WP,Bergoltz VV.Altered stability of etoposide-induced topoisomerase Il-DNA complexes in resistant human leukemia K562 cells..Br J Cancer1994;69:687-97 PMCID:PMC1968798

[57] Zwelling LA,Chan D,Sie KL.Characterization of an amsacrine-resistant line of human leukemia cells. Evidence for a drug-resistant form of topoisomerase II..J Biol Chem1989;264:16411-20

[58] Christie M,Róna G,Stewart AG.Structural biology and regulation of protein import into the nucleus..J Mol Biol2016;428:2060-90

[59] Gardiner LP,Hammonds TR.The N-terminal domain of human topoisomerase II alpha is a DNA-dependent ATPase..Biochemistry1998;37:16997-7004

[60] Campbell S.The ATP-operated clamp of human DNA topoisomerase II alpha: hyperstimulation of ATPase by “piggy-back” binding..J Mol Biol2002;320:171-88

[61] Hu T,Hsieh TS.ATPase domain of eukaryotic DNA topoisomerase II. Inhibition of ATPase activity by the anti-cancer drug bisdioxopiperazine and ATP/ADP-induced dimerization..J Biol Chem2002;277:5944-51

[62] Austin CA,Swan RL,Manville CM.TOP2B: the first thirty years..Int J Mol Sci2018;19:E2765 PMCID:PMC6163646

[63] Cowell IG.Do transcription factories and TOP2B provide a recipe for chromosome translocations in therapy-related leukemia?.Cell Cycle2012;11:3143-4 PMCID:PMC3466504

[64] Cowell IG,Smith K,Manville CM.Model for MLL translocations in therapy-related leukemia involving topoisomerase IIβ-mediated DNA strand breaks and gene proximity..Proc Natl Acad Sci U S A2012;109:8989-94 PMCID:PMC3384169